Immunomodulatory Roles of IL-15 in Immune Cells and its Potential for Cancer Immunotherapy

被引:1
|
作者
Liu, Youhan [1 ]
Ma, Wen [1 ]
Tian, Xuewen [1 ]
Wang, Qinglu [1 ]
Lu, Xin [1 ]
Luo, Ying [2 ]
Xv, Jun [1 ]
机构
[1] Shandong Sport Univ, Grad Sch Educ, Jinan 250102, Peoples R China
[2] Zibo Cent Hosp, Dept Clin Lab, Zibo 255000, Peoples R China
关键词
Tumor; NK; CD8+T; B cell; IL-15; natural killer; NATURAL-KILLER-CELLS; CD8(+) T-CELLS; LARGE ESTABLISHED TUMORS; ALPHA-CHAIN; B-CELLS; HOMEOSTATIC PROLIFERATION; HUMAN INTERLEUKIN-15; GROWTH-FACTOR; EXPRESSION; NK;
D O I
10.2174/0118715206321574240821112747
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Interleukin-15 (IL-15) was identified in 1994 as a T-cell growth factor with the capability to mimic the functions of IL-2. IL-15 engages with the IL-15R alpha subunit expressed on the surface of antigen-presenting cells (APCs) and, through a trans-presentation mechanism, activates the IL-2/IL-15R beta gamma complex receptor on the surface of natural killer (NK) cells and CD8+ T cells. This interaction initiates a cascade of downstream signaling pathways, playing a pivotal role in the activation, proliferation, and anti-apoptotic processes in NK cells, CD8+ T cells, and B cells. It provides a substantial theoretical foundation and potential therapeutic targets for tumor immunotherapy. Whether through active or passive immunotherapeutic strategies, IL-15 has emerged as a critical molecule for stimulating anti-tumor cell proliferation.
引用
收藏
页码:1457 / 1466
页数:10
相关论文
共 50 条
  • [41] Teaching tired T cells to fight HIV: time to test IL-15 for immunotherapy?
    Mastroianni, CM
    d'Ettorre, G
    Forcina, G
    Vullo, V
    TRENDS IN IMMUNOLOGY, 2004, 25 (03) : 121 - 125
  • [42] Rationale for IL-15 superagonists in cancer immunotherapy (vol 20, pg 705, 2020)
    Knudson, K. M.
    Hodge, J. W.
    Schlom, J.
    Gameiro, S. R.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (05) : I - I
  • [43] Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy
    Ying Zhang
    Qinghui Zhuang
    Fang Wang
    Can Zhang
    Chang Xu
    Aiqin Gu
    William H. Zhong
    Yi Hu
    Xiaosong Zhong
    Journal of Translational Medicine, 20
  • [44] Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy
    Qiyue Hu
    Xin Ye
    Xiangdong Qu
    Dongbing Cui
    Lei Zhang
    Zhibin Xu
    Hong Wan
    Lianshan Zhang
    Weikang Tao
    Scientific Reports, 8
  • [45] 2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy
    Peng, Yingjun
    Fu, Shengyu
    Zhao, Qi
    JOURNAL OF LEUKOCYTE BIOLOGY, 2022, 112 (04) : 823 - 834
  • [46] Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy
    Xu, Xiaojing
    Sun, Qing
    Yu, Xiao
    Zhao, Lixiang
    VIRUS RESEARCH, 2017, 233 : 35 - 41
  • [47] Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy
    Ma, Shoubao
    Caligiuri, Michael A.
    Yu, Jianhua
    TRENDS IN IMMUNOLOGY, 2022, 43 (10) : 833 - 847
  • [48] Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy
    Hu, Qiyue
    Ye, Xin
    Qu, Xiangdong
    Cui, Dongbing
    Zhang, Lei
    Xu, Zhibin
    Wan, Hong
    Zhang, Lianshan
    Tao, Weikang
    SCIENTIFIC REPORTS, 2018, 8
  • [49] A Self-Activating IL-15 Chimeric Cytokine Receptor to Empower Cancer Immunotherapy
    Chen, Sumei
    Yang, Lingrong
    Xia, Bing
    Zhu, Haitao
    Piao, Zhenghao
    Jounaidi, Youssef
    IMMUNOTARGETS AND THERAPY, 2024, 13 : 513 - 524
  • [50] Visualization of IL-15 expression in innate immune cells during homeostasis and inflammation
    Stoklasek, Thomas
    Colpitts, Sara
    Obar, Joshua
    Guo, Caiying
    Lefrancois, Leo
    JOURNAL OF IMMUNOLOGY, 2010, 184